Emergency Department and Short Stay Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
Emergency Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.
Int J Clin Pract. 2020 Oct;74(10):e13584. doi: 10.1111/ijcp.13584. Epub 2020 Jun 29.
The presence of iron deficiency (ID) in patients with acute heart failure (AHF) is high. There are few studies on the characteristics of these patients and the safety of ferric carboxymaltose administration (FCM).
Study the differences among patients with AHF based on the presence and type of ID as well as the safety of FCM administration in these patients.
The AHF-ID study is a multicentre, analytical, prospective follow-up cohort including patients admitted to six Spanish hospitals for AHF. ID was defined as serum ferritin <100 μg/L (group A) or ferritin 100-299 μg/L with a TSAT <20% (group B). In cases receiving FCM the appearance of adverse events was analysed. Adjusted Cox regression was used to determine the association with 30-days reattendance for AHF after discharge.
A total of 221 patients were recruited; 191 (86.4%) presented ID, 121 (63.4%) group A and 70 (36.6%) group B. There were scarce differences between the groups analysed. No differences were found in 30-days reattendance for AHF. FCM was administered to 158 (71.5%) patients, with 8 (5.1%) presenting adverse events, the most frequent being digestive alterations. Treatment was not discontinued in any case.
There are scarce differences between the presence and the type of ID in patients with AHF. The administration of FCM in patients with ID and AHF is safe.
急性心力衰竭（AHF）患者存在铁缺乏（ID）的情况较为常见。目前关于这些患者的特征以及铁羧麦芽糖铁（FCM）给药的安全性的研究较少。
根据 ID 的存在和类型，研究 AHF 患者之间的差异，并评估 FCM 在这些患者中的安全性。
AHF-ID 研究是一项多中心、分析性、前瞻性随访队列研究，纳入了六家西班牙医院因 AHF 入院的患者。将血清铁蛋白<100μg/L（A 组）或铁蛋白 100-299μg/L 但转铁蛋白饱和度（TSAT）<20%（B 组）定义为 ID。分析接受 FCM 治疗的患者不良事件的发生情况。采用校正 Cox 回归分析确定与出院后 30 天再次因 AHF 就诊的相关性。
共纳入 221 例患者，其中 191 例（86.4%）存在 ID，121 例（63.4%）为 A 组，70 例（36.6%）为 B 组。两组间差异较小。两组患者在 30 天因 AHF 再次就诊的差异无统计学意义。158 例（71.5%）患者接受了 FCM 治疗，其中 8 例（5.1%）出现不良反应，最常见的是消化道改变。在任何情况下均未停止治疗。
AHF 患者 ID 的存在和类型之间差异较小。ID 和 AHF 患者中使用 FCM 是安全的。
